Narotham Thudi, MD
Hematology & Oncology · Irving, TXNPI 1861401788
Payments from drug & device makers
Across 121 payments — averaging $183.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GE HealthCare$11K
- Bristol Myers Squibb$3K
- Novartis$2K
- Beigene USA, Inc.$1K
- Janssen Scientific Affairs, LLC$1K
- Daiichi Sankyo Inc.$1K
- plus $3K from 30 others
What the payments were for
- Consulting fees$6,64361%
- Food & beverage$2,03819%
- Education$831%
- Other$2,16420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GE HealthCare | 8 | $11,256 |
| Bristol Myers Squibb | 9 | $2,560 |
| Novartis | 30 | $2,287 |
| Beigene USA, Inc. | 2 | $1,313 |
| Janssen Scientific Affairs, LLC | 1 | $1,170 |
| Daiichi Sankyo Inc. | 3 | $1,074 |
| AstraZeneca | 6 | $997 |
| Myriad Genetic Laboratories, Inc. | 2 | $197 |
| Pfizer | 14 | $185 |
| E.r. Squibb & Sons, L.L.C. | 2 | $120 |
| Gilead(2 entities) | 5 | $119 |
| AbbVie | 5 | $115 |
| Merck | 4 | $89 |
| Sobi, Inc | 2 | $53 |
| Kyowa Kirin, Inc. | 2 | $52 |
| Eisai Inc. | 2 | $48 |
| Pharmaessentia USA Corporation | 2 | $42 |
| Seagen Inc. | 3 | $38 |
| Incyte Corporation | 2 | $37 |
| Adaptive Biotechnologies Corporation | 1 | $34 |
| Regeneron Healthcare Solutions, Inc. | 1 | $34 |
| Astellas Pharma US Inc | 1 | $29 |
| Lilly USA, LLC | 1 | $28 |
| Acrotech Biopharma Inc. | 1 | $28 |
| Array Biopharma Inc | 1 | $27 |
| Pharmacosmos Therapeutics Inc. | 1 | $27 |
| AVEO Pharmaceuticals, Inc. | 1 | $26 |
| Myovant Sciences Inc. | 1 | $26 |
| Johnson & Johnson | 1 | $26 |
| EMD Serono, Inc. | 1 | $25 |
| Caris MPI, Inc. | 1 | $24 |
| Geron Corporation | 1 | $24 |
| Karyopharm Therapeutics Inc. | 1 | $22 |
| Sanofi | 1 | $20 |
| GSK | 1 | $15 |
| Amgen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Revlimid$2,424
- RYBREVANT$1,170
- EndoPredict$122
- Enhertu$115
- OPDIVO$105
How this compares
$22,183 in reported general payments places this provider in the 55th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 35 | $592,178 |
| JakafiRuxolitinib Phosphate | 30 | $488,981 |
| LenvimaLenvatinib Mesylate | 19 | $430,810 |
| RevlimidLenalidomide | 27 | $428,583 |
| InlytaAxitinib | 20 | $340,543 |
| TagrissoOsimertinib Mesylate | 19 | $320,040 |
| NubeqaDarolutamide | 17 | $236,327 |
| SprycelDasatinib | 19 | $226,100 |
| ImbruvicaIbrutinib | 11 | $182,111 |
| PromactaEltrombopag Olamine | 22 | $154,545 |
| EliquisApixaban | 145 | $104,123 |
| XareltoRivaroxaban | 34 | $27,205 |
| Abiraterone Acetate | 13 | $6,305 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 81 | $2,034 |
| Anastrozole | 135 | $1,550 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence, Tagrisso | $997 | $912,21754 claims |
| Incyte CorporationJakafi | $37 | $488,98130 claims |
| PfizerInlyta, Eliquis | $185 | $444,666165 claims |
| Eisai Inc.Lenvima | $48 | $430,81019 claims |
| Bristol Myers SquibbRevlimid | $2,560 | $428,58327 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $120 | $226,10019 claims |
| NovartisPromacta | $2,287 | $154,54522 claims |
| Johnson & JohnsonXarelto | $26 | $27,20534 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $1,170 | $6,30513 claims |
| Lilly USA, LLCOlanzapine | $28 | $15630 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in Irving
- Shiraj SenIrving$2.7M
- Elias JabbourHouston$264.1M
- Luhua WangHouston$79.6M
- Courtney DinardoHouston$74M
- Jorge Cortes-FrancoHouston$59.4M
- William WierdaHouston$58.7M
- Koji SasakiHouston$39.2M
- Kyriakos PapadopoulosSan Antonio$18.5M
- Loretta NastoupilHouston$18.3M
- Christopher FlowersHouston$17.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.